Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for Benitec Biopharma (BNTC) over the last 7 years, with Q2 2025 value amounting to $6.1 million.

  • Benitec Biopharma's Share-based Compensation rose 124559.47% to $6.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $17.4 million, marking a year-over-year increase of 199951.81%. This contributed to the annual value of $17.4 million for FY2025, which is 199951.81% up from last year.
  • Per Benitec Biopharma's latest filing, its Share-based Compensation stood at $6.1 million for Q2 2025, which was up 124559.47% from $7.7 million recorded in Q1 2025.
  • Over the past 5 years, Benitec Biopharma's Share-based Compensation peaked at $7.7 million during Q1 2025, and registered a low of -$48000.0 during Q4 2022.
  • For the 5-year period, Benitec Biopharma's Share-based Compensation averaged around $1.1 million, with its median value being $237000.0 (2021).
  • Per our database at Business Quant, Benitec Biopharma's Share-based Compensation tumbled by 12008.37% in 2022 and then surged by 393333.33% in 2025.
  • Quarter analysis of 5 years shows Benitec Biopharma's Share-based Compensation stood at $239000.0 in 2021, then tumbled by 120.08% to -$48000.0 in 2022, then surged by 293.75% to $93000.0 in 2023, then soared by 3274.19% to $3.1 million in 2024, then soared by 94.68% to $6.1 million in 2025.
  • Its Share-based Compensation stands at $6.1 million for Q2 2025, versus $7.7 million for Q1 2025 and $3.1 million for Q4 2024.